Obesity Drugs: New Treatment Strategies for MASLD and MASH

Standing at the bus stop near the intersection of Michigan Avenue and Randolph Street in downtown Chicago this morning, I couldn’t facilitate but notice how the conversation among commuters has shifted over the past year. What was once casual chat about Cubs games or deep-dish pizza spots has increasingly turned to discussions about prescription weight management options—a reflection of a national trend now playing out in real time across the Windy City’s diverse neighborhoods.

This shift comes amid growing clinical interest in how medications originally developed for diabetes and obesity might address related liver conditions. A recent AJMC report highlighted emerging research suggesting that GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) could offer new treatment pathways for metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH). While the study focused on biochemical mechanisms, the implications for communities like Chicago—where obesity rates remain a public health priority—are immediately tangible.

Looking back to just a few years ago, the landscape was markedly different. Before 2021, options were largely limited to older medications like phentermine or orlistat, which worked primarily through appetite suppression or fat absorption blockade. The arrival of injectable semaglutide marked a turning point, followed by tirzepatide’s dual GIP/GLP-1 action in 2023. Now, as noted in the Obesity Medicine Association’s April 2026 update, we’ve seen the introduction of oral semaglutide formulations—a development that could significantly improve accessibility for Chicago residents who prefer pills over injections or face barriers to regular clinic visits for shots.

What makes this particularly relevant locally is how these medical advances intersect with Chicago’s specific health challenges. According to city health data referenced in broader public health discussions, certain South and West Side neighborhoods experience disproportionately high rates of obesity-related conditions. The potential for these newer medications to address not just weight but similarly comorbid liver issues represents a possible avenue for reducing long-term healthcare burdens in communities served by institutions like Cook County Health & Hospitals System and UI Health.

Of course, any discussion of these medications must include important caveats emphasized by medical authorities. The Cleveland Clinic’s weight loss medications guide, last updated September 2025, consistently stresses that these drugs are not standalone solutions but tools to be used alongside lifestyle modifications under professional supervision. They carry potential side effects ranging from gastrointestinal discomfort to more serious risks requiring monitoring—a point reinforced in FDA resources noting that all prescription medications for weight management come with possible adverse reactions requiring patient-provider dialogue.

Given my background in public health communications, if this trend impacts you in Chicago, here are the three types of local professionals you need to know about when considering weight management medications:

First, seek board-certified obesity medicine specialists who maintain active fellowship in the Obesity Medicine Association and have hospital privileges at major academic centers like Northwestern Memorial Hospital or Rush University Medical Center. These physicians stay current through continuing education on evolving pharmacotherapies and understand how to tailor treatment to individual comorbidities—crucial when considering medications that may affect liver enzymes or interact with other prescriptions common in older adults.

Second, look for registered dietitians specializing in medical nutrition therapy for metabolic conditions, ideally those affiliated with Chicago-based academic medical centers or federally qualified health centers. The best practitioners don’t just provide generic meal plans; they understand how to optimize nutrition alongside specific medications—addressing potential side effects like nausea while ensuring adequate protein intake to preserve muscle mass during weight loss, a consideration particularly relevant for aging populations in neighborhoods like Edgewater or Lakeview.

Third, establish care with a primary care physician who coordinates with specialists and has experience managing patients on GLP-1-based therapies. In Chicago’s fragmented healthcare landscape, finding a doctor who communicates effectively with endocrinologists at institutions like the University of Chicago Medicine or hepatologists at Northwestern’s Feinberg School of Medicine can make the difference between fragmented care and a cohesive treatment plan addressing both weight and related conditions like prediabetes or elevated liver enzymes.

Ready to find trusted professionals? Browse our complete directory of top-rated experts in the Chicago area today.